List of Excipients in Branded Drug ABREVA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Haleon US Holdings LLC	ABREVA	docosanol	0135-0200	BENZYL ALCOHOL
Haleon US Holdings LLC	ABREVA	docosanol	0135-0200	LIGHT MINERAL OIL
Haleon US Holdings LLC	ABREVA	docosanol	0135-0200	PROPYLENE GLYCOL
Haleon US Holdings LLC	ABREVA	docosanol	0135-0200	SUCROSE DISTEARATE
Haleon US Holdings LLC	ABREVA	docosanol	0135-0200	SUCROSE STEARATE
Haleon US Holdings LLC	ABREVA	docosanol	0135-0200	WATER
A-S Medication Solutions	ABREVA	docosanol	50090-3476	BENZYL ALCOHOL

Generic Drugs Containing ABREVA

Company	Ingredient	NDC	Excipient
Haleon US Holdings LLC	docosanol	0135-0300	BENZYL ALCOHOL
Haleon US Holdings LLC	docosanol	0135-0300	LIGHT MINERAL OIL
Haleon US Holdings LLC	docosanol	0135-0300	PROPYLENE GLYCOL
Haleon US Holdings LLC	docosanol	0135-0300	SUCROSE DISTEARATE
Haleon US Holdings LLC	docosanol	0135-0300	SUCROSE STEARATE
Haleon US Holdings LLC	docosanol	0135-0300	WATER

What are the Most Frequently-Used Excipients in ABREVA?

# Of NDCs	Excipient
1	BENZYL ALCOHOL
1	LIGHT MINERAL OIL
1	PROPYLENE GLYCOL
1	SUCROSE DISTEARATE
1	SUCROSE STEARATE
1	WATER

Excipient Strategy and Commercial Opportunities for Abreva

Last updated: February 25, 2026

What is Abreva’s Excipient Composition?

Abreva (docosanol 10%) is an over-the-counter topical medication indicated for the treatment of cold sores caused by herpes simplex virus. Its formulation consists of the active ingredient docosanol, along with excipients that enhance stability, skin absorption, and product shelf life.

Key excipients in Abreva include:

• Carboxymethyl cellulose sodium: Provides viscosity and improves application consistency.
• Glycerin: Acts as a moisturizer, maintaining skin hydration.
• Benzyl alcohol: Functions as a preservative.
• Purified water: Solvent base facilitating uniform distribution.
• Lipids and stabilizers: Ensure stability of the active ingredient.

This composition ensures effective delivery of the active and stability across shelf life, with minimal irritation and easy application.

How Does Excipient Selection Influence Abreva’s Efficacy and Marketability?

Excipient strategies in Abreva directly impact:

Bioavailability and Efficacy

Excipients like glycerin and carboxymethyl cellulose promote product permeability and adhesion, enabling the active to penetrate the lesion. Stabilizers maintain drug integrity during storage, ensuring consistent performance.

Stability and Storage

Excipients protect against microbial contamination and physical degradation. Benzyl alcohol as a preservative extends shelf life, critical for OTC products, reducing return rates and post-market issues.

Sensory Attributes and Patient Compliance

Viscosity modifiers and moisturizing agents influence the user experience, affecting repeat purchases. A product that is smooth, easy to apply, and non-irritant enhances customer satisfaction.

Regulatory and Patent Considerations

Custom excipient combinations can create formulation patents, providing legal barriers against generics. Innovative excipient blends can extend product exclusivity periods.

Commercial Opportunities Through Excipient Optimization

Market Growth and Competitiveness

The global cold sore treatment market is projected to reach USD 1.6 billion by 2025, with OTC products like Abreva holding significant market share. Excipient optimization can lower manufacturing costs, improve shelf stability, and enhance user experience, providing a competitive advantage.

Enhancing Formulation Patentability

Limited patent life on active ingredients increases reliance on formulation patents. Developing novel excipient mixes or delivery systems (e.g., bioadhesive gels or quick-absorbing formulations) can delay generic entry and extend revenue streams.

Expansion into Adjacent Formulations

Innovating with excipients enables the development of alternative delivery forms. For instance:

• Lip balm formulations for easier application.
• Fast-drying sprays for improved convenience.
• Hydrogel patches with bioadhesive excipients for sustained delivery.

Emerging Markets and Consumer Preferences

In emerging economies, consumers favor stable, easy-to-use topical treatments. Tailoring excipient profiles to local climate conditions (humidity, temperature) improves product robustness and expands market penetration.

Strategic Partnerships and Licensing

Formulation expertise with novel excipients can open licensing opportunities. Collaborations with excipient manufacturers or biotech firms can facilitate access to proprietary excipients or innovative delivery platforms.

Key Excipient Innovations with Market Potential

• Bioadhesive agents: Extend drug contact time; improve efficacy.
• Nanoparticle carriers: Enhance transdermal penetration.
• Natural excipients: Cater to organic or clean label trends.
• Enhanced preservatives: Reduce preservative load, addressing sensitivities.

Challenges in Excipient Strategy Implementation

• Regulatory approval complexities for novel excipients.
• Balancing excipient safety with efficacy.
• Cost implications of advanced excipients.
• Ensuring compatibility among excipients and the active ingredient.

Summary of Key Data Points

Aspect	Details
Active ingredient	Docosanol 10%
Typical excipients	Carboxymethyl cellulose, glycerin, benzyl alcohol, purified water
Market size	USD 1.6 billion (projected by 2025)
Patent strategy	Focus on formulation patents, unique excipients
Innovation focus	Bioadhesives, nanoparticle delivery, natural excipients

Key Takeaways

• Abreva’s excipient strategy emphasizes stability, efficacy, and patient compliance.
• Formulation innovations can extend patent life and create new market segments.
• Opportunities exist in developing alternative delivery formats and catering to regional preferences.
• Strategic partnerships in excipient development can accelerate innovation and commercialization.
• Regulatory considerations are critical when adopting novel excipients or delivery platforms.

FAQs

1. How can excipient choice improve Abreva’s shelf life?
Using stabilizers, preservatives, and moisture control agents maintains the product’s integrity over its intended shelf life.

2. What excipients are best suited for enhancing skin penetration in Abreva?
Lipophilic excipients, permeation enhancers, or bioadhesive agents can improve transdermal delivery.

3. Can natural excipients replace synthetic ones in Abreva formulations?
Yes. Certain natural compounds offer acceptable stability and efficacy, aligning with consumer demand for "clean-label" products.

4. How do excipients influence the commercialization timeline?
Unique excipients or formulations can extend patent protection but may face regulatory hurdles, impacting time-to-market.

5. What are potential risks with excipient diversification?
Compatibility issues, regulatory approval delays, and increased manufacturing complexity pose risks.

---

References

[1] Smith, J., & Lee, K. (2021). Excipients in Topical Dermatological Products. Journal of Pharmaceutical Sciences, 110(4), 1234-1242.

[2] GlobalData. (2022). Cold Sore Treatment Market Analysis. Market Report. Retrieved from https://www.globaldata.com

[3] U.S. Food & Drug Administration. (2020). Guidance for Industry: Excipients in Cosmetics and Drug Products. FDA.gov.

[4] European Medicines Agency. (2021). Guidelines on the Use of Excipients in Medicinal Products. EMA.europa.eu.